Study summary
A personalized mRNA vaccine succeeded in phase 3 for the first time
42%lower risk of recurrence or death
What was tested
Intismeran autogene (V940/mRNA-4157), a vaccine built from each patient's own tumor mutations, plus pembrolizumab, against pembrolizumab alone, after surgery for high-risk stage IIB-IV melanoma.
What they found
- Adding the vaccine lowered the risk of recurrence or death by 42%.
- Distant spread was also reduced.
- Overall survival data are not yet mature; no new safety signals.
What it means
The first phase 3 win for an individualized cancer vaccine in any cancer. Not yet approved.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.